<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Treatment with <z:chebi fb="0" ids="27690">acetazolamide</z:chebi> for <z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">pseudotumor cerebri</z:e> (PTC) in a renal transplant patient led to an <z:hpo ids='HP_0011009'>acute</z:hpo>, but reversible deterioration in renal function </plain></SENT>
<SENT sid="1" pm="."><plain>Possible pathogenetic mechanisms behind <z:hpo ids='HP_0001919'>acute renal failure</z:hpo> and <z:chebi fb="0" ids="27690">acetazolamide</z:chebi> are detailed </plain></SENT>
<SENT sid="2" pm="."><plain>In summary, caution should be exercised in <z:hpo ids='HP_0000001'>all</z:hpo> patients with <z:hpo ids='HP_0003774'>chronic renal failure</z:hpo> who require <z:chebi fb="0" ids="27690">acetazolamide</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>It should be avoided if possible, used in reduced doses when necessary, and coupled with a high fluid intake to avoid <z:hpo ids='HP_0001944'>dehydration</z:hpo> and/or intraluminal obstruction </plain></SENT>
</text></document>